Versant Ventures' Pep2Tango: A Multi-Receptor Biotech Aiming to Transform Obesity Treatment

Pep2Tango, a new biotech initiative launched by Versant Ventures, aims to transform the landscape of obesity treatment through its innovative multi-receptor approach. This entrepreneurial effort seeks to improve upon current GLP-1-based therapies by using tetra-receptor agonist peptides to target GLP-1, GIP, amylin, and calcitonin receptors simultaneously[1][2]. Such a multi-target strategy could mitigate issues such as muscle mass loss and improve tolerability, thus potentially offering more superior weight loss solutions than existing treatments like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The company, led by President and CEO Cristina Rondinone, Ph.D., and Chief Scientific Officer Soumitra Ghosh, Ph.D., is working toward IND-enabling studies with plans for an IND submission in the near future[1].